Skip to content

Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan

Comparison of Early Versus Late Administration of Insulin Glargine in Patients With type1 Diabetes During Fasting Ramadan

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04383990
Enrollment
185
Registered
2020-05-12
Start date
2020-02-28
Completion date
2020-11-30
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasting, Insulin, Type1diabetes

Keywords

Type1 Diabetes, Fasting, Insulin Glargine, Ramadan, Hypoglycemia

Brief summary

To compare different timing of insulin Glargine administration (early-6 pm versus standard bedtime-10 pm) as part of standard of care in patients with type1 diabetes who wish to fast the month of Ramadan.

Detailed description

The investigators aim to compare the effectiveness and safety of two management strategies currently used in basal insulin adjustment for treatment of Type1 diabetes (T1DM) during fasting the holy month of Ramadan. Primary Objective: To determine if taking basal insulin Glargine at 6 pm is associated with less rates of hypoglycemia -(we will consider glucose level of 70 mg/dl ( 3.9 mmol/l) and below as the level of hypoglycemia ) - compared to bedtime timing (10-12pm) during fasting Ramadan in patients with T1DM Secondary Objectives: 1. To estimate the difference between the two groups in glucose variability 2. To estimate the difference between the two groups in number of days they needed to brake their fast 3. To assess the difference in glycemic control between the two groups 4. To estimate the difference between the two groups in overnight and daytime hyperglycemia. 5. To estimate the difference between the two groups in rate of severe hyperglycemia and /or DKA It is a multi-center open label randomized study that will take place in the diabetes/Endocrine clinics at National Guards Hospitals in four cities (Jeddah, Riyadh, Alhasa, and Dammam) Variables to be Assessed: 1. Patient's demographics including (age, gender, type and duration of diabetes), and baseline measurements (weight, height,BMI, …). 2. Rate of Hypoglycemic events (as per SMBG records and CGM) in both groups 3. Number of days fasting was broken in both groups 4. Rate of severe hyperglycemic episodes (BG\>250mg/dl) or DKA in both groups 5. Mean blood glucose for the month of Ramadan as calculated from sum of each patient's 7-point blood sugar home measurements in both groups. 6. Mean 24-hour blood glucose as measured by a continuous glucose monitoring devise in both groups. 7. Mean fasting blood glucose for the month period as calculated from patients home blood sugar measurements in both groups. 8. Mean 2-hour post-prandial blood glucose for the as calculated from patients home blood sugar measurements in both groups. 9. Fructosamine and HbA1c level before and after Ramadan in both groups Results of this study will help fill a current gap of knowledge and may also contribute to the development of future guidelines for the management of type1DM during Ramadan.

Interventions

OTHERTiming of taking insulin

To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)

Sponsors

King Abdullah International Medical Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open label Randomized

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. DM type 1 2. Age \> 14 years 3. Diagnosis of type 1 DM of more than 6 months. 4. Committed to do SMBG

Exclusion criteria

1. Renal and hepatic impairment 2. Adrenal insufficiency 3. Pregnancy 4. Alcohol consumption 5. Any diagnosed psychiatric disease

Design outcomes

Primary

MeasureTime frameDescription
Hypoglycemia incidenceThrough study completion, an average of 3 monthsTo determine if taking basal insulin Glargine at 6 pm is associated with less rates of hypoglycemia -(we will consider glucose level of 70 mg/dl ( 3.9 mmol/l) and below as the level of hypoglycemia ) - compared to bedtime timing (10-12pm) during fasting Ramadan in patients with T1DM.

Secondary

MeasureTime frameDescription
Glucose variabilityThrough study completion, an average of 3 monthsTo estimate the difference between the two groups in glucose variability as measured by standard deviation on glucose monitoring
Days fast brokenThrough study completion, an average of 3 monthsTo estimate the difference between the two groups in number of days they needed to brake their fast
Glycemic controlThrough study completion, an average of 3 monthsTo assess the difference in glycemic control between the two groups as measured by hbA1c and frucosamine before and after Ramadan
HyperglycemiaThrough study completion, an average of 3 monthsTo estimate the difference between the two groups in overnight and daytime rates of hyperglycemia (BG \> 250 mg/dl)
Acute diabetes complicationsThrough study completion, an average of 3 monthsTo estimate the difference between the two groups in rate of severe hyperglycemia (hypoglycemia associated with need for outside assisstance) and /or presentation to ER with Diabetic Keto-acidosis (DKA)

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026